Literature DB >> 8333039

Intrathymic injection of donor alloantigens induces specific tolerance to cardiac allografts.

J A Goss1, Y Nakafusa, S Yu, M W Flye.   

Abstract

The induction of donor-specific tolerance would eliminate the risk of long-term immunosuppression while ensuring allograft function and survival. Male Buffalo (RT1b) rats were exposed to donor alloantigen by an intrathymic, intrasplenic, s.c., or i.v. injection of 25 x 10(6) syngeneic Buffalo (RT1b) or MHC fully mismatched Lewis (RT1l), ACI (RT1a), or UV-B irradiated Lewis (RT1l) splenocytes. The Buffalo recipients were given 1 cc of rabbit antirat antilymphocyte serum (ALS) i.p. at the time of the donor antigen injection, and 21 days later received a heterotopic Lewis or ACI heart transplant. Only intrathymic alloantigen injection induced a donor-specific tolerance which allowed the cardiac allograft to survive indefinitely (mean survival time [MST] > 176.8 days) in > 86% of the recipients without the need for further immunosuppression, whereas groups receiving antigen injections at other sites rejected cardiac allografts in control time (MST approximately 7.0 days). Histologic examination of long-term tolerated Lewis cardiac allografts revealed the presence of healthy cardiac myocytes without mononuclear infiltration. Buffalo rats with a long-term surviving Lewis cardiac allograft did not reject a second Lewis cardiac allograft (MST > 100.0 days), but rejected a heterotopic ACI cardiac allograft in normal time (MST approximately 7.0 days). By limiting dilution analysis (LDA), maturation of donor-specific CTLs (pCTL) from long-term recipient splenocytes was markedly diminished, whereas third party pCTL was not altered, and T helper-precursors were moderately decreased without alteration in the peripheral CD4+ and CD8+ phenotype frequencies. MLC responses of recipients with long-term surviving cardiac allografts to donor-specific and third party stimulation were not significantly different from naive controls. Microchimerism is unlikely because Lewis allograft survival was also prolonged (MST > 96.0 days) in rats receiving UV-B irradiated Lewis splenocytes which cannot proliferate. The absence of increased allograft survival after transfer of long-term recipient splenocytes into naive animals suggests that donor-specific suppressor cells are not present. Additionally, in vitro lymphocyte proliferative responses to mitogenic or allogeneic stimulation in MLC was not diminished by the addition of these long-term recipient splenocytes. This model emphasizes the importance of exposure of T cell precursors to foreign donor alloantigen in the thymic environment for the development of unresponsiveness to a donor-specific vascularized allograft.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8333039     DOI: 10.1097/00007890-199307000-00031

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

1.  Thymic dendritic cells traffic to thymi of allogeneic recipients and prolong graft survival.

Authors:  Steven R Duncan; Nickolas G Capetanakis; Brian R Lawson; Argyrios N Theofilopoulos
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

2.  Pretransplant intrathymic inoculation of donor antigen combined with FK506 treatment: prolongation of survival of cardiac, but not renal, allografts in rats.

Authors:  K Motoyama; T Kamei; T Arima; M Ueki; T Hirano; Y Nakafusa; M Tanaka
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

3.  Role of the thymus in transplantation tolerance in miniature swine. I. Requirement of the thymus for rapid and stable induction of tolerance to class I-mismatched renal allografts.

Authors:  K Yamada; P R Gianello; F L Ierino; T Lorf; A Shimizu; S Meehan; R B Colvin; D H Sachs
Journal:  J Exp Med       Date:  1997-08-18       Impact factor: 14.307

Review 4.  Immune Tolerance Therapy: A New Method for Treatment of Traumatic Brain Injury.

Authors:  Ruo-Yang Feng; Qian Chen; Wei-Jian Yang; Xiao-Guang Tong; Zhi-Ming Sun; Hua Yan
Journal:  Chin Med J (Engl)       Date:  2018-08-20       Impact factor: 2.628

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.